Ocriplasmin an option for FTMH and vitreomacular adhesion

Article

Ocriplasmin (Jetrea, ThromboGenics) is an option for the management of patients who have full-thickness macular hole (FTMH) and vitreomacular adhesion, according to an article in press in the American Journal of Ophthalmology.

Ocriplasmin (Jetrea, ThromboGenics) is an option for the management of patients who have full-thickness macular hole (FTMH) and vitreomacular adhesion, according to an article in press in the American Journal of Ophthalmology.

US researchers conducted two multicentre, randomized, double-masked clinical trials. The goal was characterize both visual and anatomic outcomes in patients with FTMH at baseline in ocriplasmin Phase III clinical trials. The researchers focused on resolution of vitreomacular adhesion and its relationship with FTMH closure. Among the study’s secondary endpoints was pharmacologic FTMH closure.

The researchers evaluated patients who had baseline FTMH for FTMH width, vitreomacular adhesion, and epiretinal membrane, and obtained OCT scans at baseline and at every post-injection visit.

They found that in patients who had small and medium FTMH at baseline, ocriplasmin treatment demonstrated efficacy in closure. This also held true in patients who at baseline had FTMH without epiretinal membrane. In addition, when hole closure was achieved after ocriplasmin treatment, visual acuity gains occurred more frequently compared to when this outcome did not occur.

Their findings:

 

• In ocriplasmin-injected patients who had baseline FTMH width of ≤250 μm, 58.3% had FTMH closure, compared to 16.0% of patients who received a vehicle injection only.

• In ocriplasmin-injected patients who had baseline FTMH width of >250 to ≤400 μm, 36.8% had FTMH closure, compared to 5.3% of patients who received a vehicle injection only.

• Of the patients who had FTMH at baseline and received ocriplasmin treatment, 72.1% of those who achieved hole closure at day 28 demonstrated a ≥2-line visual acuity gain at month 6, compared to 25.4% who did not achieve hole closure at day 28.

 

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.